P/E at 31.98 vs Industry's 32.51: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Slight Discount to Industry Average

The P/E ratio of Sun Pharmaceutical Industries Ltd at 31.98 is just below the sector average of 32.51, indicating a valuation discount of approximately 1.6%. This suggests that the market is pricing the stock slightly more conservatively relative to its peers in Pharmaceuticals & Biotechnology. Given the sector’s typical valuation range, this premium or discount can reflect investor sentiment about growth prospects, risk factors, or recent earnings trends. The near-parity with the industry P/E implies that valuation is not a significant outlier for the stock, but subtle differences may be signalling caution or opportunity depending on other factors. Previously rated Buy, what is Sun Pharmaceutical Industries Ltd’s current rating?

Performance Across Timeframes: Mixed Momentum

Examining the stock’s returns reveals a complex performance profile. Over the past year, Sun Pharmaceutical Industries Ltd has declined by 5.29%, underperforming the Sensex’s 2.70% loss. However, the shorter three-month period tells a different story, with the stock gaining 3.24% while the Sensex fell by 5.84%. This suggests a recent shift in momentum, possibly reflecting company-specific developments or sector rotation. The one-month return of -5.75% contrasts with the Sensex’s 4.74% gain, indicating some volatility and short-term weakness within that timeframe. Year-to-date, the stock’s loss of 1.59% is less severe than the Sensex’s 9.56% decline, highlighting relative resilience in the current calendar year.

The daily and weekly performances also show positive signs. The stock rose 4.47% on the latest trading day, outpacing the Sensex’s 0.53% gain, and recorded a 1.46% increase over the past week compared to the Sensex’s 1.84% decline. This short-term strength amid broader medium-term weakness raises questions about the sustainability of the recent rally — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — the moving average configuration provides the clearest answer.

Moving Average Configuration: Bearish Technical Setup

Technically, Sun Pharmaceutical Industries Ltd is trading below all key moving averages: 5-day, 20-day, 50-day, 100-day, and 200-day. This comprehensive positioning below short and long-term averages indicates the stock remains in a downtrend despite recent short-term gains. The failure to break above even the shortest moving averages suggests that the recent bounce may be a temporary relief rather than a sustained reversal. Such a configuration often signals caution for investors, as the stock has yet to demonstrate technical strength to confirm a trend change.

Sector Context: Pharmaceuticals & Biotechnology Performance

The Pharmaceuticals & Biotechnology sector has seen mixed results recently. Among the stocks that have declared results so far, one has reported positive outcomes, with none flat or negative. This suggests a cautiously optimistic environment within the sector. However, the sector’s average P/E of 32.51 reflects relatively high valuations, consistent with growth expectations and innovation-driven prospects. Should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider? The current rating provides the answer.

Rating Context: Previously Rated Buy, Now Reassessed

Sun Pharmaceutical Industries Ltd was previously rated Buy by MarketsMOJO, with a Mojo Score of 62.0. The rating was updated on 21 Apr 2026, reflecting a reassessment of the company’s fundamentals, valuation, and technicals. While the exact current rating is not disclosed, the data-driven approach considers the stock’s valuation close to industry average, mixed performance across timeframes, and bearish moving average configuration. This comprehensive analysis underscores the complexity of the stock’s current standing within its sector and market.

Long-Term Performance: Outperformance Over Several Years

Despite recent volatility, Sun Pharmaceutical Industries Ltd has delivered strong returns over longer horizons. The three-year return stands at 72.96%, significantly outperforming the Sensex’s 27.08%. Over five years, the stock has surged 164.64%, nearly triple the Sensex’s 57.47% gain. However, the ten-year return of 107.93% trails the Sensex’s 195.71%, indicating that while the stock has been a robust performer in recent years, it has lagged the broader market over the last decade. This long-term perspective adds depth to the current valuation and performance analysis, highlighting the stock’s cyclical nature and evolving market position.

Market Capitalisation and Sector Positioning

With a market capitalisation of ₹4,06,051.45 crore, Sun Pharmaceutical Industries Ltd is firmly positioned as a large-cap stock within the Pharmaceuticals & Biotechnology sector. This scale provides it with significant resources and market influence, but also subjects it to heightened scrutiny and expectations. The sector’s performance and valuation trends inevitably impact the stock’s trajectory, making it essential to monitor both company-specific and broader industry developments.

Conclusion: A Complex Data-Driven Picture

The data for Sun Pharmaceutical Industries Ltd reveals a stock trading at a valuation close to its industry peers, with a mixed performance profile that includes recent short-term gains amid longer-term weakness. The technical setup remains bearish, with the stock below all major moving averages, suggesting caution. The sector’s positive result declarations contrast with the stock’s uneven returns, while the rating reassessment from Buy to Hold by MarketsMOJO reflects this complexity. Investors analysing this stock must weigh the valuation, performance divergences, and technical signals carefully — what is the current rating for Sun Pharmaceutical Industries Ltd?

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →